Roche announces phase III study results of Zelboraf for adjuvant treatment of BRAF V600 mutation-positive melanoma

Roche today announced data for the phase III BRIM8 study, which was designed to investigate the efficacy and safety of Zelboraf ® (vemurafenib) in the adjuvant (after surgery) treatment of people with completely resected, BRAF V600 mutation-positive melanoma.
Source: Roche Media News - Category: Pharmaceuticals Source Type: news